Tags

Type your tag names separated by a space and hit enter

Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma.
J Laryngol Otol. 2008 Aug; 122(8):824-8.JL

Abstract

OBJECTIVE

This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas.

STUDY DESIGN AND SETTING

Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds.

RESULTS

All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded.

CONCLUSIONS

Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined.

SIGNIFICANCE

Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas.

Authors+Show Affiliations

Department of Otolaryngology, Head and Neck Surgery, Stanford University Medical Center, Stanford, CA 94305, USA. edamrose@ohns.stanford.eduNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17908354

Citation

Damrose, E J., and J F. Damrose. "Botulinum Toxin as Adjunctive Therapy in Refractory Laryngeal Granuloma." The Journal of Laryngology and Otology, vol. 122, no. 8, 2008, pp. 824-8.
Damrose EJ, Damrose JF. Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma. J Laryngol Otol. 2008;122(8):824-8.
Damrose, E. J., & Damrose, J. F. (2008). Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma. The Journal of Laryngology and Otology, 122(8), 824-8.
Damrose EJ, Damrose JF. Botulinum Toxin as Adjunctive Therapy in Refractory Laryngeal Granuloma. J Laryngol Otol. 2008;122(8):824-8. PubMed PMID: 17908354.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma. AU - Damrose,E J, AU - Damrose,J F, Y1 - 2007/10/02/ PY - 2007/10/3/pubmed PY - 2008/9/16/medline PY - 2007/10/3/entrez SP - 824 EP - 8 JF - The Journal of laryngology and otology JO - J Laryngol Otol VL - 122 IS - 8 N2 - OBJECTIVE: This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas. STUDY DESIGN AND SETTING: Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds. RESULTS: All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded. CONCLUSIONS: Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined. SIGNIFICANCE: Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas. SN - 1748-5460 UR - https://www.unboundmedicine.com/medline/citation/17908354/Botulinum_toxin_as_adjunctive_therapy_in_refractory_laryngeal_granuloma_ L2 - https://www.cambridge.org/core/product/identifier/S0022215107000710/type/journal_article DB - PRIME DP - Unbound Medicine ER -